Please assess the completion status of the following clinical trial:

Trial Title: Tailored Hydration for the Prevention of Post-ERCP Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients older than 20 years undergoing ERCP for the 1st time will be recruited~Exclusion Criteria:~* Age below 20 or above 80 years~* Underlying severe psychiatric illness~* Cardiac insufficiency (\>New York Heart Association Class II heart failure)~* Renal insufficiency (eGFR \<30mililiter/min/1.73m2)~* Respiratory insufficiency (defined as oxygen saturation \< 90%)~* Poorly controlled blood sugar~* Ongoing hypotension including those with sepsis~* Ongoing acute pancreatitis~* Underlying disease of chronic pancreatitis~* Clinical signs of hypervolemia~* Hyponatremia (Na+ levels \< 130 milliequivalent (mEq)/L))~* Hypernatremia (Na+ levels \> 150mEq/L)~* Hyperkalemia (5.1 mEq/dL)~* Metabolic alkalosis~* Past history of endoscopic sphincterectomy or endoscopic papillary balloon dilatation

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tailored standard hydration (Type: ACTIVE_COMPARATOR): Patients will be randomly allocated to tailored standard hydration arm. Patients will receive hydration with lactated Ringer's solution with rate of 1.5 milliliter(mL)/kg/hr during and after ERCP. Hydration and feeding will be tailored by each patient's symptoms and serum amylase levels.
- Tailored aggressive hydration (Type: EXPERIMENTAL): Patients will be randomly allocated to tailored aggressive hydration arm. Patients will receive hydration with lactated Ringer's solution with rate of 3.0 milliliter(mL)/kg/hr during and after ERCP and bolus injection of 20mL/kg over 1 hour after ERCP. Hydration and feeding will be tailored by each patient's symptoms and serum amylase levels.

Based on this trial design, predict the completion outcome and termination type (if applicable).